ORIG3N Secures Funding for iPSC-based Personalized Medicine Platform, includes ALS

Boston-based personalized medicine startup company ORIG3N was launched last year with the aim to develop breakthrough therapies using induced pluripotent stem cells (iPSC). The company has secured $3M in funding to expand its biorepository program, called Life Capsule, which enables patients to donate blood samples to be stored and/or used for developing individualized therapeutics. The company plans to develop iPSCs derived from these samples into a platform for drug screening, tissue engineering and research, focusing on rare genetic and neurodegenerative diseases including ALS. This is an exciting new company that could help increase the pipeline for new candidate ALS therapies!

Click here to read more.

disease-als human tissue and iPSCs iPSC topic-preclinical
Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail